Amylyx Pharmaceuticals, Inc. 8K

Amylyx Pharmaceuticals reported Q2 2026 results, noted key clinical and commercial progress around avexitide and other pipeline programs, and stated its cash runway extends into 2028 despite ongoing net losses.

On August 6, 2026, Amylyx Pharmaceuticals, Inc. reported its financial results for the quarter ended June 30, 2026, highlighting completion of the last participant’s final study visit in the 16‑week double‑blind period of the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, progress on NDA readiness and pre-commercial preparations targeting a potential 2027 launch if approved, initiation of a U.S. Expanded Access Program for avexitide, advancement of its AMX0114 ALS program and AMX0318 preclinical candidate, publication and longer-term data from the HELIOS trial of AMX0035 in Wolfram syndrome, and reaffirming a cash runway expected to fund operations into 2028 alongside a quarterly net loss of $43.4 million.

Filing Facts

CIK

1658551

Ticker

AMLX

Form

8K

Source Type

fda

Accession

0001193125-26-336670

Alert Tier

6